Filing Flows › Gossamer Bio (GOSS) › Q1 2026
Gossamer Bio (GOSS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Gossamer Bio (GOSS) reported revenue of $17.0M for the first quarter 2026 (Q1 2026), +71% from a year earlier and +23% from the quarter before. Operating margin was -264.6%, net loss $46.7M (275.2% of revenue).
Gossamer Bio, Q1 2026: revenue $17.0M (+72% year over year), operating margin -264.6%, net loss $46.7M, operating cash flow −$38.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.0M | +23% | +71% |
| Operating profit | −$44.9M | — | — |
| Net earnings | −$46.7M | — | — |
| Operating cash flow | −$38.7M | — | — |
What changed
Revenue was $17.0M in Q1 2026, up 71% year over year and up 23% from the previous quarter.
Operating costs exceeded revenue by $44.9M, an operating margin of -264.6%. Total costs grew 32% against revenue growth of 71%. The fastest-growing cost line was General & admin (+117%). The quarter ended with a net loss of $46.7M, narrower than the previous quarter's $47.2M loss.
Operating cash flow was −$38.7M. Non-cash charges added back $5K of depreciation and amortization and $6.3M of share-based compensation.
Questions
What was Gossamer Bio's revenue in the first quarter 2026?
Gossamer Bio (GOSS) reported revenue of $17.0M for the first quarter 2026 (Q1 2026), +71% from a year earlier and +23% from the quarter before.
Was Gossamer Bio profitable in the first quarter 2026?
Operating loss was $44.9M (-264.6% of revenue) and net loss $46.7M.
Source: Gossamer Bio 10-Q on SEC EDGAR.